Relative effectiveness of augmentation treatments for treatment-resistant depression: a systematic review and network meta-analysis
The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Most interventions for treatment-resistant depression (TRD) are added as augmenters. We aimed to determine the relative effectiveness of augmentation treatments for TRD. This systematic review and network meta-analysis (NMA) sought all randomized trials of pharmacological and psychological augmentation interventions for adults meeting the most common clinical criteria for TRD. The NMA compared the intervention effectiveness of depressive symptoms for TRD augmentation. Of 36 included trials, 27 were suitable for inclusion in NMA, and no psychological trials could be included in the absence of a common comparator. Antipsychotics (13 trials), mood stabilizers (three trials), NMDA-targeting medications (five trials), and other mechanisms (3 trials) were compared against placebo. NMDA treatments were markedly superior to placebo (ES = 0.91, 95% CI 0.67 to 1.16) and head-to-head NMA suggested that NMDA therapies had the highest chance of being an effective treatment option compared to other pharmacological classes. This study provides the most comprehensive evidence of augmenters' effectiveness for TRD, and our GRADE recommendations can be used to guide guidelines to optimize treatment choices. Although conclusions are limited by paucity of, and heterogeneity between, trials as well as inconsistent reports of treatment safety. This work supports the use of NMDA-targeting medications such as ketamine.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous meta-analyses have shown evidence for the use of AAs, lithium, ketamine and esketamine (Carter et al., 2020; Strawbridge et al., 2019; Vázquez et al., 2021; Zhou et al., 2015).”
From Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis (2022) · cites this paper as Carter et al., 2020
In the citing paper
“Previous studies utilizing NMA approaches have suggested the use of AAs (Zhou et al., 2015; Carter et al., 2020) as augmentation agents, although number of included trials and agents have varied across studies due to different inclusion criteria.”
From Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis (2022) · cites this paper as Carter et al., 2020
In the citing paper
“Carter et al. recently conducted a systematic review and NMA of pharmacological and psychological augmentation interventions for TRD (defined as two adequate treatments in current episode), however, no psychological trial could be included due to the absence of a common comparator (Carter et al., 2020).”
From Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis (2022) · cites this paper as Carter et al., 2020
In the citing paper
“We did not include comparisons with NMDA antagonists, such as ketamine, since those have been addressed in a previous NMA (Carter et al., 2020) and has much faster action as compared to the conventional augmentation agents”
From Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis (2022) · cites this paper as Carter et al., 2020
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., Norris, S., Falck-Ytter, Y., Glasziou, P., & deBeer, H. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.026 · Cited by 10,681
Hutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., Ioannidis, J. P. A., Straus, S., Thorlund, K., Jansen, J. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2385 · Cited by 8,269
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2462 · Cited by 894
Automating network meta‐analysis
van Valkenhoef, G., Lu, G., de Brock, B., Hillege, H., Ades, A. E., & Welton, N. J. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.1054 · Cited by 786
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
Self-citationvan Valkenhoef, G., Dias, S., Ades, A. E., & Welton, N. J. (2016) · Research Synthesis Methods · doi:10.1002/jrsm.1167 · Cited by 695
Bauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
rjags: Bayesian Graphical Models using MCMC
Plummer, M. (2008) · CRAN: Contributed Packages · doi:10.32614/cran.package.rjags · Cited by 575
Nierenberg, A. A., Fava, M., Trivedi, M. H., Wisniewski, S. R., Thase, M. E., McGrath, P. J., Alpert, J. E., Warden, D., Luther, J. F., Niederehe, G., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1519 · Cited by 559
Marcus, R. N., McQuade, R. D., Carson, W. H., Hennicken, D., Fava, M., Simon, J. S., Trivedi, M. H., Thase, M. E., & Berman, R. M. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31816774f9 · Cited by 518
A Novel Augmentation Strategy for Treating Resistant Major Depression
Shelton, R. C., Tollefson, G. D., Tohen, M., Stahl, S., Gannon, K. S., Jacobs, T. G., Buras, W. R., Bymaster, F. P., Zhang, W., Spencer, K. A., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.1.131 · Cited by 504
Berman, R. M., Marcus, R. N., Swanink, R., McQuade, R. D., Carson, W. H., Corey-Lisle, P. K., & Khan, A. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0604 · Cited by 409
Johnston, K. M., Powell, L. C., Anderson, I. M., Szabo, S., & Cline, S. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.06.045 · Cited by 321
Fekadu, A., Wooderson, S. C., Markopoulo, K., Donaldson, C., Papadopoulos, A., & Cleare, A. J. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.10.014 · Cited by 299
Self-citationBerman, R. M., Fava, M., Thase, M. E., Trivedi, M. H., Swanink, R., McQuade, R. D., Carson, W. H., Adson, D., Taylor, L., Hazel, J., et al. (2009) · CNS Spectrums · doi:10.1017/s1092852900020216 · Cited by 260
Markov chain Monte Carlo methods in biostatistics
Gelman, A., & Rubin, D. B. (1996) · Statistical Methods in Medical Research · doi:10.1177/096228029600500402 · Cited by 255
Fonagy, P., Rost, F., Carlyle, J., McPherson, S., Thomas, R., Pasco Fearon, R. M., Goldberg, D., & Taylor, D. (2015) · World Psychiatry · doi:10.1002/wps.20267 · Cited by 237
Su, T.-P., Chen, M.-H., Li, C.-T., Lin, W.-C., Hong, C.-J., Gueorguieva, R., Tu, P.-C., Bai, Y.-M., Cheng, C.-M., & Krystal, J. H. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.94 · Cited by 209
Zhou, X., Ravindran, A. V., Qin, B., Del Giovane, C., Li, Q., Bauer, M., Liu, Y., Fang, Y., da Silva, T., Zhang, Y., et al. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14r09204 · Cited by 189
Eisendrath, S. J., Gillung, E., Delucchi, K. L., Segal, Z. V., Nelson, J. C., McInnes, L. A., Mathalon, D. H., & Feldman, M. D. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000442260 · Cited by 187
Thase, M. E., Youakim, J. M., Skuban, A., Hobart, M., Augustine, C., Zhang, P., McQuade, R. D., Carson, W. H., Nyilas, M., Sanchez, R., et al. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09688 · Cited by 182
Ionescu, D. F., Bentley, K. H., Eikermann, M., Taylor, N., Akeju, O., Swee, M. B., Pavone, K. J., Petrie, S. R., Dording, C., Mischoulon, D., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.09.037 · Cited by 179
A randomized add-on trial of high-dose d-cycloserine for treatment-resistant depression
Heresco-Levy, U., Gelfin, G., Bloch, B., Levin, R., Edelman, S., Javitt, D. C., & Kremer, I. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000910 · Cited by 177
Baumann, P., Nil, R., Souche, A., Montaldi, S., Baettig, D., Lambert, S., Uehlinger, C., Kasas, A., Amey, M., & Jonzier-Perey, M. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199608000-00006 · Cited by 173
Thase, M. E., Youakim, J. M., Skuban, A., Hobart, M., Zhang, P., McQuade, R. D., Nyilas, M., Carson, W. H., Sanchez, R., & Eriksson, H. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09689 · Cited by 165
Husain, M. I., Chaudhry, I. B., Husain, N., Khoso, A. B., Rahman, R. R., Hamirani, M. M., Hodsoll, J., Qurashi, I., Deakin, J. F., & Young, A. H. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117724352 · Cited by 144
Self-citationPatkar, A. A., Masand, P. S., Pae, C.-U., Peindl, K., Hooper-Wood, C., Mannelli, P., & Ciccone, P. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000246212.03530.fd · Cited by 140
Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis
Strawbridge, R., Carter, B., Marwood, L., Bandelow, B., Tsapekos, D., Nikolova, V. L., Taylor, R., Mantingh, T., de Angel, V., Patrick, F., et al. (2019) · British Journal of Psychiatry · doi:10.1192/bjp.2018.233 · Cited by 140
Self-citationEfficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression
Maes, M. H. J., Vandoolaeghe, E., & Desnyder, R. (1996) · Journal of Affective Disorders · doi:10.1016/s0165-0327(96)00089-4 · Cited by 125
Carvalho, A. F., Berk, M., Hyphantis, T. N., & McIntyre, R. S. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000357500 · Cited by 123
Self-citationDomany, Y., Bleich-Cohen, M., Tarrasch, R., Meidan, R., Litvak-Lazar, O., Stoppleman, N., Schreiber, S., Bloch, M., Hendler, T., & Sharon, H. (2019) · British Journal of Psychiatry · doi:10.1192/bjp.2018.196 · Cited by 114
Lithium Augmentation of Nortriptyline for Subjects Resistant to Multiple Antidepressants
Nierenberg, A. A., Papakostas, G. I., Petersen, T., Montoya, H. D., Worthington, J. J., Tedlow, J., Alpert, J. E., & Fava, M. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200302000-00013 · Cited by 103
Dunner, D. L., Amsterdam, J. D., Shelton, R. C., Loebel, A., & Romano, S. J. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0714 · Cited by 80
Long-term lithium treatment in the prevention of suicidal behavior in bipolar disorder patients
Tondo, L., & Baldessarini, R. J. (2009) · Epidemiologia e Psichiatria Sociale · doi:10.1017/s1121189x00000439 · Cited by 79
Barbee, J. G., Thompson, T. R., Jamhour, N. J., Stewart, J. W., Conrad, E. J., Reimherr, F. W., Thompson, P. M., & Shelton, R. C. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05355gre · Cited by 78
Augmentation strategies for treatment-resistant depression
Carvalho, A. F., Machado, J. R., & Cavalcante, J. L. (2009) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32831be9ef · Cited by 78
Self-citationBauer, M., Dell’Osso, L., Kasper, S. F., Pitchot, W., Vansvik, E. D., Köhler, J., Jørgensen, L., & Montgomery, S. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.05.079 · Cited by 73
Hobart, M., Skuban, A., Zhang, P., Augustine, C., Brewer, C., Hefting, N., Sanchez, R., & McQuade, R. D. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.17m12058 · Cited by 68
Esketamine is approved in Europe for treating resistant major depressive disorder
Mahase, E. (2019) · BMJ · doi:10.1136/bmj.l7069 · Cited by 67
Schindler, F., & Anghelescu, I. G. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328014823d · Cited by 65
Hobart, M., Skuban, A., Zhang, P., Josiassen, M. K., Hefting, N., Augustine, C., Brewer, C., Sanchez, R., & McQuade, R. D. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1430220 · Cited by 63
Fang, Y., Yuan, C., Xu, Y., Chen, J., Wu, Z., Cao, L., Yi, Z., Hong, W., Wang, Y., Jiang, K., et al. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31822bb1d9 · Cited by 59
Fava, M., Durgam, S., Earley, W., Lu, K., Hayes, R., Laszlovszky, I., & Németh, G. (2018) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000235 · Cited by 58
Santos, M. A., Rocha, F. L., & Hara, C. (2008) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.v10n0302 · Cited by 51
McAllister-Williams, R. H., Anderson, I. M., Finkelmeyer, A., Gallagher, P., Grunze, H. C. R., Haddad, P. M., Hughes, T., Lloyd, A. J., Mamasoula, C., McColl, E., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00436-8 · Cited by 47
Möller, H., Demyttenaere, K., Olausson, B., Szamosi, J., Wilson, E., Hosford, D. A., Dunbar, G. C., Tummala, R., & Eriksson, H. (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2014.989261 · Cited by 33
Girlanda, F., Cipriani, A., Agrimi, E., Appino, M. G., Barichello, A., Beneduce, R., Bighelli, I., Bisoffi, G., Bisogno, A., Bortolaso, P., et al. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-731 · Cited by 33
Ozaki, N., Otsubo, T., Kato, M., Higuchi, T., Ono, H., Kamijima, K., & ADMIRE Study Group (2014) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12214 · Cited by 32
Hauksson, P., Ingibergsdóttir, S., Gunnarsdóttir, T., & Jónsdóttir, I. H. (2017) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2017.1331263 · Cited by 29
Yoshimura, R., Kishi, T., Hori, H., Ikenouchi, A., Katsuki, A., Umene‐Nakano, W., Iwata, N., & Nakamura, J. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.07.008 · Cited by 26
Bauer, M., Hefting, N., Lindsten, A., Josiassen, M. K., & Hobart, M. (2019) · Acta Neuropsychiatrica · doi:10.1017/neu.2018.23 · Cited by 26
Kamijima, K., Kimura, M., Kuwahara, K., Kitayama, Y., & Tadori, Y. (2018) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12663 · Cited by 25
Husain, M. I., Strawbridge, R., Carter, B., Jones, B. D. M., Young, A. H., & Carvalho, A. F. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-028538 · Cited by 5
Self-citationWhat do we know about long-term treatment outcomes for severe depressive disorders?
Strawbridge, R., Jaeckle, T., & Cleare, A. J. (2020) · BJPsych Open · doi:10.1192/bjo.2020.10 · Cited by 5
Self-citation
Research works printed but not linked: 1
- Torjesen I., 2019, BMJ (Clinical Research ed.), 366, l4714
Cited by
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
“Taken together, results from meta-analyses suggest superiority of intravenous ketamine or esketamine when compared with second-generation antipsychotics (19, 143, 150, 151).”
ResultSelf-citationNovel and emerging treatments for major depression
Marwaha, S., Palmer, E., Suppes, T., Cons, E., Young, A. H., & Upthegrove, R. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02080-3 · Cited by 588
Self-citationNuñez, N. A., Joseph, B., Pahwa, M., Kumar, R., Resendez, M. G., Prokop, L. J., Veldic, M., Seshadri, A., Biernacka, J. M., Frye, M. A., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.12.134 · Cited by 215
Jones, B. D. M., Razza, L. B., Weissman, C. R., Karbi, J., Vine, T., Mulsant, L. S., Brunoni, A. R., Husain, M. I., Mulsant, B. H., Blumberger, D. M., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.25531 · Cited by 121
Self-citationScott, F., Hampsey, E., Gnanapragasam, S., Carter, B., Marwood, L., Taylor, R. W., Emre, C., Korotkova, L., Martín-Dombrowski, J., Cleare, A. J., et al. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811221104058 · Cited by 87
“Inadequate response to both pharmacological and psychological therapies was permitted, consistent with previous meta-analyses on this subject (Carter et al., 2020; Strawbridge et al., 2019) and in keeping with standardised staging of TRD (Fekadu et al.”
BackgroundMethodResultInfluentialSelf-citation
Metadata
- Authors
- Carter, B., Strawbridge, R., Husain, M. I., Jones, B. D. M., Short, R., Cleare, A. J., Tsapekos, D., Patrick, F., Marwood, L., Taylor, R. W., Mantingh, T., de Angel, V., Nikolova, V. L., Carvalho, A. F., & Young, A. H.
- Affiliations
- King's College London (GB)
- Centre for Addiction and Mental Health (CA)
- University of Toronto (CA)
- Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK;
- Corresponding author
- Young, Allan H.
- ORCID
- Venue
- International Review of Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2020-06-05
- Volume
- 32
- Issue
- 5-6
- Pages
- 477-490
- ISSN
- 0954-0261 (ISSN-L)
- 1369-1627
- OpenAlex
- W3034152700
- Cited by
- 47
- References
- 55
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 5 · 2023: 8 · 2022: 12 · 2021: 9 · 2020: 1
- FWCI
- 0.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Review of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute for Health and Care Research
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- treatment-resistant depression, antidepressant augmentation, antipsychotic drugs, mood stabilizers, NMDA receptor antagonists, ketamine, relative effectiveness, depressive symptoms
- MeSH terms
- Humans, Antipsychotic Agents, Treatment Outcome, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.